| Name | Title | Contact Details |
|---|
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
DXE Medical is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arterys Inc. opens medical imaging to the power of the cloud. Arterys developed 4D Flow technology, which generates precise measurements of blood flow noninvasively and non-radiatively anywhere in the body.
The Rhode Island Blood Center was founded in 1979 as a non-profit community blood center. Our goal is to ensure that all Rhode Islanders have immediate access to a safe and plentiful blood supply. The blood center achieves its goals by constantly
Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue restoration. The company`s initial focus is the Bridge-Enhanced® ACL Restoration (BEAR®) Implant, which represents a paradigm shift in the treatment of ACL tears from reconstruction to restoration. The BEAR technology was pioneered by Martha Murray, M.D., founder of Miach Orthopaedics, at the Boston Children`s Hospital Department of Orthopedic Surgery, with initial research funding provided by the NFL Players Association, Boston Children`s Hospital and the National Institutes of Health.